Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
KRAS crowding continues
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
A trio of new pivotal trial entries
AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.
ESMO 2023 – tarlatamab hits the target for Amgen
But late-breaking data raise questions about lack of a dose response.
World Lung 2023 – targeted therapy to the rescue in small-cell lung
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
